Full text
3/2026
vol. 35
Case report
Irreversible paraplegia due to transverse myelitis as a rare complication of CAR T-cell therapy in a patient with B-cell lymphoma
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
Department of Neurology, Poznan University of Medical Science, Poznan, Poland
Department of Neurology, Poznan University Hospital, Poznan, Poland
Department of Hematology and Bone Marrow Transplantation, Poznan University Hospital, Poznan, Poland
Adv Psychiatry Neurol 2026; 35 (3): 218-223
Data publikacji online: 2026/09/29
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-2544.
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380: 45-56.
- Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol 2025; 7: e434-e447.
- Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625-638.
- Velasco R, Mussetti A, Villagrán-García M, Sureda A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern? Front Neurol 2023; 14: 1144414. DOI: 10.3389/fneur.2023.1144414.
- Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 2024; 21: 501-521.
- Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther 2022; 28: 294-302.
- Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR‐T treatment. WIREs Mech Dis 2022; 14: e1576. DOI: https://doi.org/10.1002/wsbm.1576.
- Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin 2013; 31: 79-138.
- West T, Hess C, Cree B. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol 2012; 32: 97-113.
- Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499-505.
- Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep 2006; 6: 236-243.
- Deschênes-Simard X, Santomasso BD, Dahi PB. Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood 2024; 144: 2083-2094.
- Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, et al. Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. eJHaem 2022; 3: 223-227.
- Nair R, Drillet G, Lhomme F, Le Bras A, Michel L, Rossi J, et al. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 2020; 106: 1504-1506.
- Beauvais D, Cozzani A, Blaise AS, Moreau AS, Varlet P, Gaggero S, et al. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma. Curr Res Transl Med 2022; 70: 103331. DOI: 10.1016/j.retram.2021.103331.
- Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep 2020; 10: 18997. DOI: 10.1038/s41598-020-76055-9.
- Aghajan Y, Yu A, Jacobson CA, Kim AI, Kean L, Robertson M, et al. Myelopathy because of CAR-T-related neurotoxicity treated with siltuximab. Neurol Clin Pract 2021; 11: e944-e946. DOI: 10.1212/CPJ.0000000000001078.
- Diorio C, Hernandez-Miyares L, Espinoza DA, Banwell BL, Bar-Or A, DiNofia AM, et al. Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents. Blood 2024; 144: 1387-1398.
- Gust J, Shah NN. CARdinal signs of variant ICANS. Blood 2024; 144: 1352-1354.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
